These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 11929985)
1. CD40 stimulation leads to effective therapy of CD40(-) tumors through induction of strong systemic cytotoxic T lymphocyte immunity. van Mierlo GJ; den Boer AT; Medema JP; van der Voort EI; Fransen MF; Offringa R; Melief CJ; Toes RE Proc Natl Acad Sci U S A; 2002 Apr; 99(8):5561-6. PubMed ID: 11929985 [TBL] [Abstract][Full Text] [Related]
2. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Fransen MF; Sluijter M; Morreau H; Arens R; Melief CJ Clin Cancer Res; 2011 Apr; 17(8):2270-80. PubMed ID: 21389097 [TBL] [Abstract][Full Text] [Related]
3. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Diehl L; den Boer AT; Schoenberger SP; van der Voort EI; Schumacher TN; Melief CJ; Offringa R; Toes RE Nat Med; 1999 Jul; 5(7):774-9. PubMed ID: 10395322 [TBL] [Abstract][Full Text] [Related]
4. CD4+ T cells are able to promote tumor growth through inhibition of tumor-specific CD8+ T-cell responses in tumor-bearing hosts. den Boer AT; van Mierlo GJ; Fransen MF; Melief CJ; Offringa R; Toes RE Cancer Res; 2005 Aug; 65(15):6984-9. PubMed ID: 16061684 [TBL] [Abstract][Full Text] [Related]
6. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication. van Mierlo GJ; Boonman ZF; Dumortier HM; den Boer AT; Fransen MF; Nouta J; van der Voort EI; Offringa R; Toes RE; Melief CJ J Immunol; 2004 Dec; 173(11):6753-9. PubMed ID: 15557168 [TBL] [Abstract][Full Text] [Related]
7. Dendritic cell activation by combined exposure to anti-CD40 plus interleukin (IL)-12 and IL-18 efficiently stimulates anti-tumor immunity. Balkow S; Loser K; Krummen M; Higuchi T; Rothoeft T; Apelt J; Tuettenberg A; Weishaupt C; Beissert S; Grabbe S Exp Dermatol; 2009 Jan; 18(1):78-87. PubMed ID: 19054060 [TBL] [Abstract][Full Text] [Related]
8. Split peripheral tolerance: CD40 ligation blocks tolerance induction for CD8 T cells but not for CD4 T cells in response to intestinal antigens. Chung Y; Ko SY; Ko HJ; Kang CY Eur J Immunol; 2005 May; 35(5):1381-90. PubMed ID: 15827964 [TBL] [Abstract][Full Text] [Related]
9. Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy. Merritt RE; Yamada RE; Crystal RG; Korst RJ J Thorac Cardiovasc Surg; 2004 Feb; 127(2):355-64. PubMed ID: 14762342 [TBL] [Abstract][Full Text] [Related]
10. Generation of tumor-specific cytotoxic T lymphocyte and prolongation of the survival of tumor-bearing mice using interleukin-18-secreting fibroblasts loaded with an epitope peptide. Chung SW; Cohen EP; Kim TS Vaccine; 2004 Jun; 22(20):2547-57. PubMed ID: 15193380 [TBL] [Abstract][Full Text] [Related]
11. In vitro activation of cancer patient-derived dendritic cells by tumor cells genetically modified to express CD154. Loskog A; Tötterman TH; Böhle A; Brandau S Cancer Gene Ther; 2002 Oct; 9(10):846-53. PubMed ID: 12224026 [TBL] [Abstract][Full Text] [Related]
12. Loss of CTL function among high-avidity tumor-specific CD8+ T cells following tumor infiltration. Janicki CN; Jenkinson SR; Williams NA; Morgan DJ Cancer Res; 2008 Apr; 68(8):2993-3000. PubMed ID: 18413769 [TBL] [Abstract][Full Text] [Related]
13. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer. Kim S; Lee JB; Lee GK; Chang J Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351 [TBL] [Abstract][Full Text] [Related]
14. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity. Riquelme E; Carreño LJ; González PA; Kalergis AM Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198 [TBL] [Abstract][Full Text] [Related]
15. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy. Chamoto K; Wakita D; Narita Y; Zhang Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T Cancer Res; 2006 Feb; 66(3):1809-17. PubMed ID: 16452242 [TBL] [Abstract][Full Text] [Related]
16. Th1 cell adjuvant therapy combined with tumor vaccination: a novel strategy for promoting CTL responses while avoiding the accumulation of Tregs. Zhang Y; Wakita D; Chamoto K; Narita Y; Matsubara N; Kitamura H; Nishimura T Int Immunol; 2007 Feb; 19(2):151-61. PubMed ID: 17189593 [TBL] [Abstract][Full Text] [Related]
17. B7.2-Ig fusion proteins enhance IL-4-dependent differentiation of tumor-sensitized CD8+ cytotoxic T lymphocyte precursors. Hiraoka S; Takeuchi N; Bian Y; Nakahara H; Kogo M; Dunussi-Joannopoulos K; Wolf S; Ono S; Fujiwara H Int Immunol; 2005 Aug; 17(8):1071-9. PubMed ID: 16027141 [TBL] [Abstract][Full Text] [Related]
18. Cyclophosphamide inhibition of anti-CD40 monoclonal antibody-based therapy of B cell lymphoma is dependent on CD11b+ cells. Honeychurch J; Glennie MJ; Illidge TM Cancer Res; 2005 Aug; 65(16):7493-501. PubMed ID: 16103104 [TBL] [Abstract][Full Text] [Related]
19. Tumor regression by anti-CD40 and interleukin-2: role of CD40 in hematopoietic cells and organ-specific effects. Welniak LA; Shorts L; Subleski J; Blazar BR; Wiltrout RH; Murphy WJ Biol Blood Marrow Transplant; 2004 Aug; 10(8):534-9. PubMed ID: 15282531 [TBL] [Abstract][Full Text] [Related]
20. Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity. Liu Y; Huang H; Chen Z; Zong L; Xiang J J Gene Med; 2003 Aug; 5(8):668-80. PubMed ID: 12898636 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]